Professor Chen Muquan and Professor Chen Xiaoling spent five years successfully developing a new antihypertensive peptide. (Photo/Huang Zhiwen) Professor Chen Quanmu, director of R&D at Zhongxing University, said that hypertension is the invisible killer of cardiovascular diseases. 1 year, about10.8 million people go to the outpatient clinic for hypertension, and the medical expenses of medical insurance are as high as 25 billion yuan. About 4 people over the age of 20 in China suffer from hypertension on average 1 person, and most patients often have to associate with antihypertensive drugs for life if they fail to prevent or change their diet patterns in the early stage of hypertension.
The characteristic of "new antihypertensive peptide" is to develop a new "polypeptide" from fermented milk, which can not only be used as the key active ingredient for regulating and lowering blood pressure, but also be taken from nature without side effects.
Professor Chen Quanmu said that hypertension is the invisible killer of cardiovascular disease. 1 year, about10.8 million people go to the outpatient clinic for medical treatment because of hypertension, and the medical insurance cost is as high as 25 billion yuan. (Photo/Huang Zhiwen) Professor Chen Xiaoling, director of R&D at Daye University, said that existing studies have confirmed that bioactive peptides in milk protein have the potential to promote health. In particular, milk contains a high content of peptides, which are hydrolyzed by a special "Kefir" strain to produce "polypeptide" enzymes.
Professor Chen Xiaoling said that the R&D team has signed a technology transfer contract with China Biomedical Technology. (Photography/Huang Zhiwen) "Polypeptide" comes from natural protein. This award-winning patent belongs to the core technology of new ingredients and provides a new and purified antihypertensive polypeptide. Key sequences can come from natural protein, and can also be produced by chemical synthesis and gene recombination, which can be widely used in food, quasi-drug nutrition and medicines to regulate blood pressure or reduce the incidence of cardiovascular diseases.
At present, the invention of this domestic antihypertensive component has been patented in Taiwan Province Province, the United States and China. In order to enter the international market, we will continue to apply for multinational patents, and the R&D team has signed a contract with China Biomedical Technology for technology transfer.